Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing

Core Insights - Sernova Biotherapeutics has successfully closed a non-brokered private placement financing, securing total gross proceeds of $2.1 million by issuing 13,762,659 units at a price of $0.15 per unit [1] - Each unit consists of one common share and one common share purchase warrant exercisable at $0.25 per share for 36 months, with a four-month hold period applicable [1] - The financing, along with an additional $5.5 million committed by a board member and the anticipated retirement of approximately $17 million in debt, significantly enhances the company's balance sheet and supports the advancement of its Cell Pouch Bio-hybrid Organ clinical program aimed at treating type 1 diabetes [2] Company Overview - Sernova Biotherapeutics is a clinical-stage company focused on developing regenerative medicine therapeutics, specifically the Cell Pouch integrated with human donor cells or stem-cell derived islet-like clusters, in collaboration with Evotec [4] - The goal is to create bio-hybrid organs that restore or enhance the function of compromised organs, particularly for the treatment of type 1 diabetes [4]